Avecho Advances Phase III Insomnia Trial with Positive Interim Analysis

Phase III Insomnia Trial Clears Key Hurdle

Avecho Biotechnology (ASX:AVE) marked a pivotal moment in its development program with a positive interim analysis of its Phase III insomnia trial. The independent Data Monitoring Board (DMB) reviewed unblinded data from the first 244 participants and unanimously recommended the trial proceed to full enrolment of 519 participants without expanding the sample size. This outcome validates the trial’s original statistical assumptions and materially reduces clinical risk for the company.

Crucially, no serious adverse events were reported among participants receiving either 75mg or 150mg doses of Avecho’s CBD TPM® capsule or placebo, underscoring a favourable safety profile. This contrasts with some existing prescription sleep aids linked to next-day impairment and overdose risks, potentially bolstering the product’s commercial appeal.

Accelerated Recruitment and Regulatory Engagement

Following the DMB’s endorsement, Avecho plans to accelerate recruitment by activating additional clinical sites beyond its existing network. Operational learnings from the initial cohort will inform streamlined patient management and recruitment protocols, aiming to maintain momentum through to trial completion.

The positive interim result also strengthens Avecho’s hand in ongoing licensing discussions outside Australia and supports planned regulatory engagement with the US Food and Drug Administration and other international authorities. In Australia, successful Phase III completion is the final step before seeking Therapeutic Goods Administration approval for over-the-counter registration of the CBD TPM® capsule for insomnia management.

Financial Position Bolstered by Option Exercises and R&D Refund

Ahead of the interim analysis, Avecho raised approximately $1.9 million through the exercise of 157 million listed options (AVEOA) at $0.012 each, which expired on 10 May 2026. The lapse of remaining options materially simplifies the company’s capital structure, removing potential dilution overhang.

In tandem, Avecho received $1.98 million under the Australian Government’s Research and Development Tax Incentive Scheme for the year ended 31 December 2025. Of this, $1.62 million repaid advances from Endpoints Capital, while the balance supports ongoing operations and commercialisation efforts.

These inflows have strengthened Avecho’s balance sheet, with cash on hand reaching $6.6 million at 30 June 2026. Net cash used in operating activities was $1.1 million for the quarter, reflecting continued investment in clinical development.

Corporate Governance Updates

The quarter saw the resignation of non-executive director Matthew McNamara after more than six years of service. Avecho also appointed Naomi Lawrie as Company Secretary, effective 1 May 2026, replacing Melanie Leydin following internal team changes at the company’s corporate service provider.

Commercial and Market Potential

Avecho’s CBD TPM® insomnia product already benefits from an Australian licensing deal with Sandoz, featuring a US$3 million upfront payment and potential milestone payments up to US$16 million, plus tiered royalties. The positive interim results are expected to enhance the program’s attractiveness to partners in other territories.

With insomnia affecting up to 30% of the global population and a sleep aids market forecast to reach US$950 billion by 2032, Avecho is positioning itself to capture a meaningful share, especially in Australia where regulatory changes permit over-the-counter CBD sales from pharmacies pending approval. The company’s Phase III trial is the largest ever testing cannabidiol for insomnia in Australia, designed to meet TGA, FDA, and EMA requirements.